SI-F019 / Biokin Pharma - LARVOL DELTA

A Study of SI-F019 in Healthy Participants (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern. (PubMed, Antiviral Res) - "Comprehensive biophysical analyses revealed the mechanism of increased inhibition to be enhanced interaction of SI-F019 with all the tested spike variants, in contrast to monoclonal antibodies which tended to show weaker binding to some variants. The results imply that SI-F019 may be a broadly useful agent for treatment of COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study of SI-F019 in Healthy Participants (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

New P1 trial